saikosaponin d

**Saikosaponin d** is a triterpene saponin extracted from *Radix Bupleuri* (the root of Bupleurum falcatum), a plant used in traditional Chinese medicine[1][2][6][8]. It is classified as a small molecule and possesses a steroidal structure[9]. Saikosaponin d exhibits diverse pharmacological activities, including **antioxidant**, **anti-inflammatory**, **anticancer**, **immunomodulatory**, **anti-fibrotic**, **anti-angiogenic**, and **chemopreventive** effects[1][2][6][8][9]. Its *mechanisms of action* involve the regulation and inhibition of cellular signaling pathways related to inflammation, apoptosis, autophagy, and cell proliferation. Notably, it suppresses the p-STAT3/C/EBPβ signaling pathway, inhibiting *cyclooxygenase-2 (COX-2)* expression[3]; inhibits *SERCA* (sarcoplasmic/endoplasmic reticulum calcium ATPase)[2]; acts as a *Glucocorticoid receptor agonist*[2]; and demonstrates inhibitor activity for both *COX-2* and *inducible nitric oxide synthase (iNOS)*[2]. It additionally inhibits *MRP1* (multidrug resistance-associated protein 1), modulates PI3K/Akt/mTOR and NF-κB signaling, and has demonstrated ability to induce apoptosis, autophagy, and differentiation in cancer cells[1][2][7]. Experimental evidence primarily supports its use in disease models such as cancer, chronic liver inflammation, liver fibrosis, myocardial injury, pulmonary and renal disorders, neurological diseases, diabetes, and osteoarthritis[1][6][7][9]. Despite its potential, saikosaponin d faces challenges related to poor bioavailability, which researchers seek to address with novel formulations like nanoparticle encapsulation[1].

Other names

saikosaponin dSaikosaponin D(P)Saikosaponin D-RMSAILKOSAPONIN DSAILKOSAPONINS DSaikosaponin D(RG)beta-D-Galactopyranoside, (3beta,4alpha,16alpha)-13,28-epoxy-16,23-dihydroxyolean-11-en-3-yl 6-deoxy-3-O-beta-D-glucopyranosyl